Claims for Patent: 3,944,671

Summary for Patent: 3,944,671

Title:	Treatment of adrenal malfunction
Abstract:	Dextrorotatory .alpha.-(4-aminophenyl)-.alpha.-lower alkylglutarimides or salts thereof normalize the secretion of malfunctioning adrenal glands.
Inventor(s):	Dziemian; Robert (Cedar Knolls, NJ), Finch; Neville (West Orange, NJ)
Assignee:	Ciba-Geigy Corporation (Ardsley, NY)
Application Number:	05/396,969
Patent Claims:	1. A pharmaceutical composition for reducing adrenal hyperfunction, comprising an adrenal secretion reducing amount of the dextrorotatory antipode of an .alpha.-(4-aminophenyl)-.alpha.-lower alkylglutarimide or a therapeutically acceptable acid addition salt thereof, and a pharmaceutical excipient. 2. A composition as claimed in claim 1, wherein the antipode is d-aminoglutethimide or a therapeutically acceptable acid addition salt thereof. 3. A composition as claimed in claim 2, wherein the antipode is the d-aminoglutethimide d-tartrate. 4. A composition as claimed in claim 2, wherein the antipode is the d-aminoglutethimide monophosphate. 5. A composition as claimed in claim 1, wherein the antipode content is about 10 to 90% by weight. 6. A composition as claimed in claim 5, wherein the antipode content is about 20 to 80% by weight. 7. A composition as claimed in claim 1, containing between about 450 and about 1,000 mg of the antipode per oral unit dosage form. 8. A method of treating a mammal suffering from malfunctioning adrenal glands, which consists in administering to him enterally or parenterally an adrenal secretion reducing amount of the composition claimed in claim 1. 9. A method as claimed in claim 8, wherein the effective amount of the antipode is between about 8 and 80 mg per kilogram body weight per day of treatment. 10. A method as claimed in claim 8, wherein the effective amount of the antipode is between about 10 and 30 mg per kilogram body weight per day of treatment.